Kiffik Biomedical has developed the KIFFIK Lab, a rapid biomarker test that detects cancer by analyzing interstitial fluid (ISF) for specific cancer biomarkers. This at-home, painless test provides results within minutes, addressing the need for more accurate and accessible cancer screening methods.
Funding
$830K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer screening methods can be inaccurate, inconvenient, costly, and often rely on outdated technologies, leading to delayed diagnoses and increased anxiety for individuals at risk. Traditional screening processes may involve invasive procedures, long wait times for results, and limited accessibility, particularly for those in remote areas or with mobility issues.
Solution
Kiffik Biomedical offers the KIFFIK Lab, a rapid, at-home biomarker test designed for early cancer detection. The test analyzes interstitial fluid (ISF), a fluid found under the skin, for specific cancer biomarkers, providing results within minutes. This approach eliminates the need for blood draws, clinic visits, and lengthy waiting periods, offering a more convenient and accessible screening option. The KIFFIK Lab aims to empower individuals to take control of their health through regular, painless self-testing, enabling earlier detection and timely intervention.
Target Audience
The primary target audience includes individuals at high risk for developing cancer, particularly colon cancer, and those seeking a more convenient and accessible cancer screening method.
Features
- Rapid biomarker analysis using interstitial fluid (ISF)
- Painless and easy at-home sample collection
- Results available within minutes
- Designed for early detection of common and deadly cancers
- Eliminates the need for blood draws and clinic visits